Jackson Hole Capital Partners LLC Reduces Position in Zoetis Inc. $ZTS

Jackson Hole Capital Partners LLC decreased its holdings in shares of Zoetis Inc. (NYSE:ZTS) by 33.7% during the fourth quarter, according to the company in its most recent disclosure with the SEC. The fund owned 13,170 shares of the company’s stock after selling 6,686 shares during the quarter. Jackson Hole Capital Partners LLC’s holdings in Zoetis were worth $1,657,000 at the end of the most recent reporting period.

Other hedge funds and other institutional investors have also recently modified their holdings of the company. Summit Place Financial Advisors LLC raised its position in Zoetis by 0.4% in the 3rd quarter. Summit Place Financial Advisors LLC now owns 19,369 shares of the company’s stock valued at $2,834,000 after purchasing an additional 76 shares during the last quarter. CWA Asset Management Group LLC grew its position in Zoetis by 1.1% during the 3rd quarter. CWA Asset Management Group LLC now owns 7,236 shares of the company’s stock worth $1,059,000 after purchasing an additional 80 shares during the last quarter. YANKCOM Partnership grew its position in Zoetis by 3.5% during the 4th quarter. YANKCOM Partnership now owns 2,402 shares of the company’s stock worth $302,000 after purchasing an additional 81 shares during the last quarter. Evergreen Capital Management LLC increased its stake in Zoetis by 3.3% in the third quarter. Evergreen Capital Management LLC now owns 2,696 shares of the company’s stock valued at $394,000 after purchasing an additional 85 shares during the period. Finally, Beese Fulmer Investment Management Inc. increased its stake in Zoetis by 2.4% in the third quarter. Beese Fulmer Investment Management Inc. now owns 3,672 shares of the company’s stock valued at $537,000 after purchasing an additional 85 shares during the period. 92.80% of the stock is currently owned by hedge funds and other institutional investors.

Zoetis Price Performance

Shares of ZTS opened at $114.51 on Thursday. The company has a current ratio of 3.03, a quick ratio of 1.94 and a debt-to-equity ratio of 2.71. The stock’s 50 day moving average is $120.17 and its two-hundred day moving average is $124.86. Zoetis Inc. has a twelve month low of $112.97 and a twelve month high of $172.23. The firm has a market capitalization of $48.17 billion, a PE ratio of 19.03, a P/E/G ratio of 1.80 and a beta of 0.98.

Zoetis (NYSE:ZTS) last issued its earnings results on Thursday, February 12th. The company reported $1.48 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $1.40 by $0.08. The business had revenue of $2.39 billion during the quarter, compared to the consensus estimate of $2.36 billion. Zoetis had a return on equity of 62.02% and a net margin of 28.24%.The company’s revenue for the quarter was up 3.0% on a year-over-year basis. During the same period in the prior year, the business posted $1.40 EPS. Zoetis has set its FY 2026 guidance at 7.000-7.100 EPS. Research analysts anticipate that Zoetis Inc. will post 7.02 earnings per share for the current year.

Zoetis Announces Dividend

The firm also recently disclosed a quarterly dividend, which will be paid on Tuesday, June 2nd. Shareholders of record on Monday, April 20th will be given a $0.53 dividend. The ex-dividend date is Monday, April 20th. This represents a $2.12 annualized dividend and a yield of 1.9%. Zoetis’s dividend payout ratio is presently 35.22%.

Analysts Set New Price Targets

Several equities research analysts have recently weighed in on the stock. Weiss Ratings downgraded shares of Zoetis from a “hold (c-)” rating to a “sell (d+)” rating in a research note on Friday, March 27th. William Blair restated an “outperform” rating on shares of Zoetis in a research report on Monday, March 2nd. Piper Sandler restated a “neutral” rating and set a $135.00 price target (down from $190.00) on shares of Zoetis in a research note on Thursday, January 22nd. Bank of America increased their price target on Zoetis from $135.00 to $140.00 and gave the stock a “neutral” rating in a report on Friday, February 13th. Finally, BTIG Research reiterated a “buy” rating and issued a $160.00 price objective on shares of Zoetis in a research report on Thursday, February 26th. Seven investment analysts have rated the stock with a Buy rating, seven have issued a Hold rating and one has given a Sell rating to the company. According to MarketBeat.com, the company currently has an average rating of “Hold” and an average target price of $151.75.

About Zoetis

Zoetis Inc (NYSE: ZTS) is a global animal health company that develops, manufactures and markets a broad portfolio of products and services for companion animals and livestock. The company’s offerings include pharmaceuticals, vaccines and biologics, parasiticides and anti-infectives, as well as diagnostic instruments, consumables and laboratory testing services. Zoetis serves the veterinary community, livestock producers and other animal-health customers with products designed to prevent, detect and treat disease and to support animal productivity and welfare.

Zoetis traces its roots to the animal health business of Pfizer and became an independent, publicly traded company following a 2013 separation and initial public offering.